Forbes: CVS Caremark, the drug retailer and pharmacy benefit management firm, announced a new agreement with Aetna to help constrain drug costs. “The deal encompasses approximately $9.5 billion in annual drug spending relating to approximately 9.7 million lives. CVS expects significant long-term financial benefits from this strategic relationship” (7/28)…
Lees meer..

The biggest names in nanotechnology are preparing to gather this fall at Rice University, and everyone is welcome to join them. Registration is open for Year of Nano events to be held Oct. 10-13 in honor of the 25th anniversary of the Nobel Prize-winning discovery of the carbon 60 molecule, the buckminsterfullerene, at Rice. The Richard E…
Lees meer..

UCLA scientists have identified for the first time a cell-of-origin for human prostate cancer, a discovery that could result in better predictive and diagnostics tools and the development of new and more effective targeted treatments for the disease…
Lees meer..

Cascades of genetic signals determine which neurotransmitter a brain cell will ultimately use to communicate with other cells. Now a pair of reports from biologists at the University of California, San Diego, have shown for the first time that electrical activity in these developing neurons can alter their chemical fate - and change an animal’s behavior - by tweaking this genetic program…
Lees meer..

Despite a sluggish year, health care investors can look forward to growing emerging markets and a possible change in the U.S. political climate, Forbes reports. “Health care has not had a banner year in 2010 as the sector’s stocks have underperformed the market on account of reform in the United States and financial problems in Europe…
Lees meer..

Orexigen® Therapeutics, Inc. (Nasdaq: OREX) announced that results from its COR-I trial of Contrave® were published online in the journal Lancet. COR-I was the largest of the four, 56-week, Phase 3 trials supporting the New Drug Application for Contrave, currently under review by the U.S. Food and Drug Administration…
Lees meer..

The latest court case exploring the link between Wyeth Pharmaceuticals’ hormonal replacement drug Prempro and breast cancer started Tuesday in Philadelphia, the Philadelphia Inquirer reports…
Lees meer..

Intra-Cellular Therapies, Inc. announced the results from a Phase Ib/II clinical trial in patients with schizophrenia with ITI-007, the Company’s unique, investigational new drug for the treatment of schizophrenia. The trial met its primary endpoint demonstrating that ITI-007 was safe and well-tolerated in patients with stabilized schizophrenia…
Lees meer..

Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) announced that six of six patients (100%) in the ANA598 200 mg twice daily (bid) arm who were randomized to stop all treatment at Week 24 in an ongoing Phase II trial maintained undetectable levels of virus 12 weeks after stopping treatment, referred to as Sustained Virological Response 12, or SVR12…
Lees meer..

Shionogi Inc., a U.S.-based group company of Shionogi & Co., Ltd., announced the U.S. Food and Drug Administration approval of CUVPOSA™ (glycopyrrolate), the first liquid treatment for patients ages 3-16 who suffer from chronic severe drooling associated with neurologic conditions such as cerebral palsy. CUVPOSA™ was designated an Orphan Drug by the FDA…
Lees meer..